Korio launches RTSM platform for clinical trials

Korio launched a modern randomization and trial supply management platform built to help sponsors and CROs handle protocol changes faster, support complex studies and keep trials inspection-ready. The platform is aimed at Phase 1 through Phase 3 programs and is designed to reduce delays, workarounds and support gaps that often come with legacy systems.

Why it matters: - Clinical trial teams often need mid-study changes, but legacy RTSM systems can slow those updates and force operational workarounds. - Faster changes, stronger support and reusable study settings can cut delays and reduce cost across a sponsor’s trial portfolio. - A platform built for inspection readiness and data integrity matters for sponsors, CROs and biotech companies running regulated studies.

What happened: - Korio launched a modern RTSM platform for clinical trials on July 15, 2026. - Korio is a clinical trial technology company founded in 2021. - The platform is designed to manage randomization, trial supply and participant data across clinical studies. - Korio says the platform is built for flexible, compliant and inspection-ready trial management across every phase of a study.

The details: - The platform is designed around four readiness principles: customization, complexity, change and reuse. - Korio says the system can adapt to trial-specific needs without workarounds, rebuilds or operational disruption. - The platform supports early-phase studies through global Phase 3 programs across multiple therapeutic areas. - Korio says mid-study protocol amendments can be delivered in half the time of legacy vendors while maintaining quality and regulatory control. - Study configurations and features can be reused across later trials to improve efficiency and consistency. - Participant management includes patient visits, randomization and investigational product dispensing. - Supply management is built to provide transparency and control across the supply chain. - The platform includes an integrations framework for data exchange with external clinical systems. - Real-time alerts, reports and analytics support trial and supply decisions. - The system provides a real-time, human-readable, blind-controlled audit trail for inspection readiness. - Portfolio-wide reporting shows supply and site performance across active studies. - The platform can deploy changes across multiple trials at the same time. - Integrations monitoring is designed to support data integrity. - Automated testing validates system updates before they go live. - Korio says the platform has already shortened timelines and lowered costs for some study teams, based on a client’s experience. - A senior director of clinical operations at a client organization said the team avoided six- to 10-week waits for small changes and found Korio proactive and easy to work with. - The same client said Korio’s team helped staff members who had never used IRT before. - Korio operates only in RTSM and is not part of a broader eClinical suite. - Senior RTSM professionals guide each study from kickoff to closeout. - Sponsors have direct access to Korio’s founder-led leadership team. - Korio says the organization has more than 100 years of combined RTSM experience. - The interface is designed for site staff, including teams with no prior IRT experience. - The system uses clear navigation, embedded guidance and role-specific workflows to reduce site burden. - Korio says sponsors, CROs and biotech companies can request a demonstration. - Korio serves sponsors and CROs across the United States and the European Union. - More information

Between the lines: - Korio is positioning RTSM as a specialist category, not a feature inside a broader software suite. - The company is betting that speed, support depth and change control will matter as much as core functionality for trial operators. - The emphasis on reusable configurations and simultaneous multi-trial changes suggests a focus on portfolio-level operations, not just single studies.

What's next: - Sponsors, CROs and biotech companies can contact Korio to learn more about the platform or request a demonstration. - Korio is likely to continue targeting teams that need flexible RTSM support for complex and changing study designs.

The bottom line: - Korio is launching RTSM as a specialized platform built to move faster than legacy trial systems while staying compliant and inspection-ready.